The FDA approved omalizumab-igec (Omlyclo) as the first biosimilar for omalizumab (Xolair) and the first for any respiratory ...

Primary care clinicians are often the most accessible to patients and play a crucial role in the early detection and ...

Crizanlizumab (Adakveo) failed to outperform placebo in patients with sickle cell disease, the phase III STAND trial showed.

Adding tilsotolimod to ipilimumab did not improve response or survival outcomes in patients with advanced melanoma.

An expert explained the importance of the FDA’s approval of Ensacove for patients with ALK-positive non-small cell lung ...

A novel therapy for atopic dermatitis (AD) led to at least 75% improvement in a third of patients after 6 months, a ...

Detailed price information for Tg Therapeutics (TGTX-Q) from The Globe and Mail including charting and trades.

In September 2024, a readout from a separate trial of rocatinlimab elicited mixed reactions from analysts, who found the ...

DURHAM, N.C., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable ...

Amgen (NASDAQ: AMGN) and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) today announced new results from the ongoing ROCKET Phase 3 clinical trial program evaluating rocatinlimab, an investigational T ...

The safety profile of crizanlizumab was in line with previous findings, with pyrexia, headache, and nausea being commonly reported adverse events. Grade 3 or higher adverse events were less ...

Inc. , today announced a definitive merger agreement under which Bristol Myers Squibb ("BMS") will acquire all of the outstanding shares of 2seventy bio at a price of $5.00 per share in an all-cash ...